Lat­est news on FDA’s sec­ond look at Amy­lyx; Un­pack­ing Parkin­son’s R&D; Fiona Mar­shall takes over NI­BR from Jay Brad­ner; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

This is go­ing to be a long week­end for us at End­points, thanks to La­bor Day in the US, and it’s much need­ed. Sep­tem­ber is shap­ing up to be a busy month, with bio­phar­ma seem­ing­ly com­ing back from the sum­mer and events kick­ing in­to gear. If you have any news to share, we al­ways ap­pre­ci­ate some lead time. For the dai­ly read­ers — see you on Tues­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER